Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Huntsman Cancer Institute at the University of Utah Develops Novel Prostate Cancer Therapy

Huntsman Cancer Institute received approval from the U.S. Food and Drug Administration (FDA) for a new prostate cancer treatment that combines two cancer drugs, enzalutamide and talazoparib.

Enzalutamide is a medication commonly used for prostate cancer treatment, but the addition of talazoparib is a novel approach specifically for patients with prostate cancer. 

The phase 3 trial demonstrated that this drug combination led to a 55 percent reduction in the risk of cancer progression compared to the standard treatment available for these patients.

The novel therapy signifies an improved outlook for many patients and underscores the dedication of researchers and healthcare professionals to enhance cancer treatments and alleviate the burden of the disease.

Prostate cancer is one of the most prevalent cancer types, and it ranks as the second leading cause of cancer-related deaths among men in the United States, according to the National Cancer Institute.

The approval of this new prostate cancer therapy combining enzalutamide and talazoparib represents a significant milestone in the field of cancer treatment.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024